Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

154.38USD
22 May 2018
Change (% chg)

$0.17 (+0.11%)
Prev Close
$154.21
Open
$154.39
Day's High
$154.94
Day's Low
$154.18
Volume
43,391
Avg. Vol
776,521
52-wk High
$256.78
52-wk Low
$142.83

Latest Key Developments (Source: Significant Developments)

Allergan Announced Official Launch Of TrueTear
Friday, 13 Apr 2018 08:01am EDT 

April 13 (Reuters) - Allergan plc ::ANNOUNCED OFFICIAL LAUNCH OF TRUETEAR.  Full Article

Allergan And Richter Say Bipolar I Depression Study Meets Main Goal
Tuesday, 3 Apr 2018 08:00am EDT 

April 3 (Reuters) - Allergan Plc - For Rgh-Md ::ALLERGAN AND RICHTER ANNOUNCE POSITIVE TOPLINE RESULTS FROM THIRD OF THREE PIVOTAL TRIALS OF CARIPRAZINE IN BIPOLAR I DEPRESSION.PRIMARY ENDPOINT WAS MET IN STUDY EVALUATING PATIENTS WITH ACUTE BIPOLAR I DEPRESSION TREATED WITH CARIPRAZINE 1.5 MG VERSUS PLACEBO.CARIPRAZINE WAS GENERALLY WELL TOLERATED IN TRIAL.PLANS TO INCLUDE DATA FROM ALL THREE PIVOTAL TRIALS IN CO'S SNDA TO U.S. FDA IN SECOND HALF OF 2018.MOST COMMONLY REPORTED ADVERSE EVENTS IN CARIPRAZINE GROUPS WERE AKATHISIA, RESTLESSNESS, NAUSEA, AND FATIGUE.EFFICACY OF CARIPRAZINE IN TREATMENT OF BIPOLAR I DEPRESSION HAS BEEN DEMONSTRATED IN THREE POSITIVE PIVOTAL TRIALS.53, PRIMARY AND KEY SECONDARY EFFICACY ENDPOINTS WERE MET FOR CARIPRAZINE 1.5 MG DOSE GROUP.  Full Article

Allergan Said To Weigh Options For Women's Health Unit - Bloomberg
Monday, 2 Apr 2018 03:53pm EDT 

April 2 (Reuters) - :ALLERGAN SAID TO WEIGH OPTIONS FOR WOMEN'S HEALTH UNIT BLOOMBERG, CITING SOURCES‍​ - BLOOMBERG, CITING SOURCES‍​.  Full Article

Amgen And Allergan Receive Positive CHMP Opinion For Abp 980
Friday, 23 Mar 2018 08:41am EDT 

March 23 (Reuters) - Allergan Plc ::AMGEN AND ALLERGAN RECEIVE POSITIVE CHMP OPINION FOR ABP 980 (BIOSIMILAR HERCEPTIN®) FOR THE TREATMENT OF THREE TYPES OF CANCER.AMGEN ‍RECOMMENDED FOR APPROVAL FOR SAME INDICATIONS AS HERCEPTIN​.AMGEN CHMP POSITIVE OPINION FOR ABP 980 WILL NOW BE REVIEWED BY EUROPEAN COMMISSION.  Full Article

Revance Therapeutics, Mylan Ireland Enter Collaboration Deal‍
Wednesday, 28 Feb 2018 04:17pm EST 

Feb 28 (Reuters) - Revance Therapeutics Inc <>::REVANCE THERAPEUTICS SAYS ‍CO, MYLAN IRELAND LIMITED ENTERED INTO COLLABORATION DEAL- SEC FILING​.REVANCE THERAPEUTICS - ‍MYLAN AGREED TO PAY CO NON-REFUNDABLE UPFRONT PAYMENT OF $25 MILLION WITH CONTINGENT PAYMENTS OF UP TO $100 MILLION.REVANCE THERAPEUTICS - ‍CONTINGENT PAYMENTS BASED UPON ACHIEVEMENT OF SPECIFIED MILESTONES, SPECIFIED, TIERED SALES MILESTONES OF UP TO $225 MILLION​.REVANCE THERAPEUTICS INC - ‍MYLAN WILL PAY REVANCE ROYALTIES ON SALES OF BIOSIMILAR IN MYLAN TERRITORIES​.REVANCE THERAPEUTICS - ‍MYLAN MAY ELECT TO HAVE DRUG PRODUCT MANUFACTURED BY ANOTHER PARTY.REVANCE THERAPEUTICS INC - CO GRANTED MYLAN EXCLUSIVE, LICENSE TO CO'S INTELLECTUAL PROPERTY RIGHTS FOR DEVELOPMENT, COMMERCIALIZATION OF BIOSIMILAR​.REVANCE THERAPEUTICS INC - CO WILL BE PRIMARILY RESPONSIBLE FOR NON-CLINICAL DEVELOPMENT ACTIVITIES, CLINICAL DEVELOPMENT ACTIVITIES IN N. AMERICA​.  Full Article

Mylan To Bring Biosimilar Of Botox To Market Through Collaboration With Revance Therapeutics
Wednesday, 28 Feb 2018 04:05pm EST 

Feb 28 (Reuters) - Mylan Nv ::MYLAN TO BRING A BIOSIMILAR OF BOTOX TO THE MARKET THROUGH A COLLABORATION AND LICENSE AGREEMENT WITH REVANCE THERAPEUTICS.MYLAN NV - ‍COLLABORATION AND LICENSE DEAL FOR DEVELOPMENT AND COMMERCIALIZATION OF A PROPOSED BIOSIMILAR TO BOTOX​.MYLAN NV - ‍COLLABORATION INCLUDES AN UPFRONT PAYMENT OF $25 MILLION TO REVANCE​.MYLAN TO BRING A BIOSIMILAR OF BOTOX TO THE MARKET THROUGH A COLLABORATION AND LICENSE AGREEMENT WITH REVANCE THERAPEUTICS.  Full Article

Mylan NV Defeats Allergan's Maneuver To Rent Tribal Sovereign Immunity To Avoid Restasis Patent Challenge
Monday, 26 Feb 2018 08:00am EST 

Feb 26 (Reuters) - Mylan NV ::MYLAN NV - ‍U.S. PTAB DENIED ST. REGIS MOHAWK TRIBE'S MOTION TO TERMINATE CO'S PATENT CHALLENGE REGARDING 6 PATENTS RELATED TO ALLERGAN'S RESTASIS​.  Full Article

FDA Acceptance Of Medicines360's Filing For Supplemental NDA For Liletta 52 Mg
Thursday, 22 Feb 2018 08:00am EST 

Feb 22 (Reuters) - Allergan Plc ::FDA ACCEPTANCE OF MEDICINES360'S FILING FOR SUPPLEMENTAL NEW DRUG APPLICATION FOR LILETTA® (LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM) 52 MG.  Full Article

Allergan Files For Potential Mixed Shelf Offering
Friday, 16 Feb 2018 05:16pm EST 

Feb 16 (Reuters) - Allergan Plc ::ALLERGAN PLC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Allergan Declares Q1 2018 Cash Dividend Of $0.72 Per Share
Friday, 9 Feb 2018 08:00am EST 

Feb 9 (Reuters) - Allergan Plc ::ALLERGAN DECLARES FIRST QUARTER 2018 CASH DIVIDEND OF $0.72 PER ORDINARY SHARE AND PROVIDES ANNUAL GENERAL MEETING OF SHAREHOLDERS UPDATES.  Full Article

BRIEF-Allergan Exercises Option To Acquire Compound From Aptinyx Discovery Platform

* ALLERGAN EXERCISES OPTION TO ACQUIRE COMPOUND FROM APTINYX DISCOVERY PLATFORM UNDER ONGOING RESEARCH COLLABORATION